Results 121 to 130 of about 2,439,563 (414)

Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study

The Lancet Oncology, 2019
Summary Background Few studies have investigated the risks of subsequent primary neoplasms after adolescent and young adult (AYA) cancer. We investigated the risks of specific subsequent primary neoplasms after each of 16 types of AYA cancer. Methods The
C. Bright, R. Reulen, D. Winter, D. Stark, M. McCabe, A. B. Edgar, C. Frobisher, M. Hawkins   +7 more
semanticscholar   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, Volume 20, Issue 6, Page 1591-1611, June 2026.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

DP133 | CIP2A IS IMPLICATED IN RUXOLITINIB RESISTANCE IN MYELOFIBROSIS

Haematologica
Although ruxolitinib (Ruxo) is the standard of care for patients (pts) with myelofibrosis (MF), therapeutic resistance develops in approximately 50% within 3-5 years, posing a clinical challenge.
M. Balliu, M. Vannucchi, M.C. Siciliano, M. Lomi, C. Basile, P. Guglielmelli, A.M. Vannucchi   +6 more
doaj  

Endocardial Neoplasm [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease

American journal of hematology/oncology, 2019
Myeloid neoplasms with germline DDX41 mutations have been incorporated into the 2017 WHO classification. Limited studies describing the clinicopathologic features and mutation profile are available.
Andrés E Quesada, M. Routbort, C. Dinardo, C. Bueso-Ramos, R. Kanagal-Shamanna, J. Khoury, B. Thakral, Z. Zuo, C. Yin, S. Loghavi, C. Ok, Sa A. Wang, Zhenya Tang, Sarah Bannon, C. Benton, G. Garcia-Manero, H. Kantarjian, R. Luthra, L. Medeiros, K. Patel   +19 more
semanticscholar   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Deciphering of intra‐tumoural heterogeneity and the interplay between metastasis‐associated meta‐program and myofibroblasts in gastric cancer

Clinical and Translational Medicine
Background Gastric cancer (GC) exhibits high heterogeneity that relies on the oncogenic properties of cancer cells and multicellular interactions in the tumour microenvironment.
Xiongyan Wu, Zhijian Jin, Baolong Li, Yifan Lu, Junyi Hou, Lizhong Yao, Zhenjia Yu, Qingqing Sang, Beiqin Yu, Jianfang Li, Chen Li, Chao Yan, Zhenggang Zhu, Kaiwen Tang, Bingya Liu, Liping Su   +15 more
doaj   +1 more source

Thymic Epithelial Neoplasm by AJCC v8 Stage [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Vitiligo and neoplasms

Acta Dermato-Venereologica, 1972
No abstract ...
A, Lassus, A, Apajalahti, K, Blomqvist, M, Mustakallio, U, Kiistala   +4 more
openaire   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, Volume 20, Issue 6, Page 1612-1625, June 2026.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source